-
1
-
-
84856784474
-
Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
-
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl 2):e44S-88S.
-
(2012)
Chest
, vol.141
, pp. e44S-e88S
-
-
Ageno, W.1
Gallus, A.S.2
Wittkowsky, A.3
Crowther, M.4
Hylek, E.M.5
Palareti, G.6
-
2
-
-
34447317298
-
Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study
-
Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007;116(2):180-7.
-
(2007)
Circulation
, vol.116
, Issue.2
, pp. 180-187
-
-
Agnelli, G.1
Gallus, A.2
Goldhaber, S.Z.3
Haas, S.4
Huisman, M.V.5
Hull, R.D.6
-
3
-
-
84880327613
-
Oral apixaban for the treatment of acute venous thromboembolism
-
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine 2013;369(9):799-808.
-
(2013)
New England Journal of Medicine
, vol.369
, Issue.9
, pp. 799-808
-
-
Agnelli, G.1
Buller, H.R.2
Cohen, A.3
Curto, M.4
Gallus, A.S.5
Johnson, M.6
-
4
-
-
55549147508
-
Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases
-
Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008;28(11):1354-73.
-
(2008)
Pharmacotherapy
, vol.28
, Issue.11
, pp. 1354-1373
-
-
Baetz, B.E.1
Spinler, S.A.2
-
5
-
-
84856798208
-
Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
-
Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells P, Stevenson MD, et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e351S-418S.
-
(2012)
Chest
, vol.141
, Issue.2
, pp. e351S-e418S
-
-
Bates, S.M.1
Jaeschke, R.2
Stevens, S.M.3
Goodacre, S.4
Wells, P.5
Stevenson, M.D.6
-
6
-
-
47649098524
-
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
-
Botticelli Investigators, Writing Committee, Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis 2008;6(8):1313-8.
-
(2008)
Journal of Thrombosis and Haemostasis
, vol.6
, Issue.8
, pp. 1313-1318
-
-
Buller, H.1
Deitchman, D.2
Prins, M.3
Segers, A.4
-
7
-
-
33746899054
-
The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee
-
Boudes PF. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contemporary Clinical Trials 2006;27(5):432-40.
-
(2006)
Contemporary Clinical Trials
, vol.27
, Issue.5
, pp. 432-440
-
-
Boudes, P.F.1
-
8
-
-
70349306707
-
Dabigatran versus warfarin in patients with atrial fibrillation
-
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2009;361(12):1139-51.
-
(2009)
New England Journal of Medicine
, vol.361
, Issue.12
, pp. 1139-1151
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
Eikelboom, J.4
Oldgren, J.5
Parekh6
-
9
-
-
84890783342
-
Analysing data and undertaking meta-analyses
-
(editors) Higgins JPT, Green S (editors), Version 5.1.0 [updated March 2011]. The Cochrane Collaboration
-
Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
-
(2011)
Cochrane Handbook for Systematic Reviews of Interventions
-
-
Deeks, J.J.1
Higgins, J.P.T.2
Altman, D.G.3
-
10
-
-
77950880770
-
Update on antithrombotic therapy: new anticoagulants
-
Eikelboom JW, Weitz JI. Update on antithrombotic therapy: new anticoagulants. Circulation 2010;121(13):1523-32.
-
(2010)
Circulation
, vol.121
, Issue.13
, pp. 1523-1532
-
-
Eikelboom, J.W.1
Weitz, J.I.2
-
11
-
-
78650619315
-
Oral rivaroxaban for symptomatic venous thromboembolism
-
EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine 2010;363(26):2499-510.
-
(2010)
New England Journal of Medicine
, vol.363
, Issue.26
, pp. 2499-2510
-
-
Bauersachs, R.1
Berkowitz, S.D.2
Brenner, B.3
Buller, H.R.4
Decousus, H.5
-
12
-
-
0141636587
-
A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I
-
Eriksson H, Wåhlander K, Gustafsson D, Welin LT, Frison L, Schulman S, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Journal of Thrombosis and Haemostasis 2003;1(1):41-7.
-
(2003)
Journal of Thrombosis and Haemostasis
, vol.1
, Issue.1
, pp. 41-47
-
-
Eriksson, H.1
Wåhlander, K.2
Gustafsson, D.3
Welin, L.T.4
Frison, L.5
Schulman, S.6
-
13
-
-
35449007749
-
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial
-
Eriksson BI, Dahl OE, Rosenecher N, Kurth AA, van Dijk CN, Frostick SP, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Journal of Thrombosis and Haemostasis 2007;5(11):2178-85.
-
(2007)
Journal of Thrombosis and Haemostasis
, vol.5
, Issue.11
, pp. 2178-2185
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosenecher, N.3
Kurth, A.A.4
van Dijk, C.N.5
Frostick, S.P.6
-
14
-
-
57449094606
-
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development
-
Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clinical Pharmacokinetics 2009;48(1):1-22.
-
(2009)
Clinical Pharmacokinetics
, vol.48
, Issue.1
, pp. 1-22
-
-
Eriksson, B.I.1
Quinlan, D.J.2
Weitz, J.I.3
-
15
-
-
84869838484
-
Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials
-
Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012;345:e7498.
-
(2012)
BMJ
, vol.345
-
-
Fox, B.D.1
Kahn, S.R.2
Langleben, D.3
Eisenberg, M.J.4
Shimony, A.5
-
16
-
-
0035944369
-
Prevention and treatment of postphlebitic syndrome: results of a 3-part study
-
Ginsberg JS, Hirsh J, Julian J, Vander LaandeVries M, Magier D, MacKinnon B, et al. Prevention and treatment of postphlebitic syndrome: results of a 3-part study. Archives of Internal Medicine 2001;161(17):2105-9.
-
(2001)
Archives of Internal Medicine
, vol.161
, Issue.17
, pp. 2105-2109
-
-
Ginsberg, J.S.1
Hirsh, J.2
Julian, J.3
Vander LaandeVries, M.4
Magier, D.5
MacKinnon, B.6
-
17
-
-
70049099036
-
Assessing risk of bias in included studies
-
(editors) Higgins JPT, Green S (editors), Version 5.1.0 [updated March 2011]. The Cochrane Collaboration
-
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
-
(2011)
Cochrane Handbook for Systematic Reviews of Interventions
-
-
Higgins, J.P.T.1
Altman, D.G.2
Sterne, J.A.C.3
-
18
-
-
34248559871
-
Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom
-
Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of Internal Medicine 2007;167(9):935-43.
-
(2007)
Archives of Internal Medicine
, vol.167
, Issue.9
, pp. 935-943
-
-
Huerta, C.1
Johansson, S.2
Wallander, M.A.3
Garcia Rodriguez, L.A.4
-
19
-
-
0028853354
-
Relationship between changes in the deep venous system and the development of the postthrombotic syndrome after an acute episode of lower limb deep vein thrombosis: a one-to six-year follow-up
-
discussion 313
-
Johnson BF, Manzo RA, Bergelin RO, Strandness DE Jr. Relationship between changes in the deep venous system and the development of the postthrombotic syndrome after an acute episode of lower limb deep vein thrombosis: a one-to six-year follow-up. Journal of Vascular Surgery 1995;21(2):307-12; discussion 313.
-
(1995)
Journal of Vascular Surgery
, vol.21
, Issue.2
, pp. 307-312
-
-
Johnson, B.F.1
Manzo, R.A.2
Bergelin, R.O.3
Strandness, D.E.4
-
20
-
-
0036727049
-
The post-thrombotic syndrome: current knowledge, controversies and directions for future research
-
Kahn SR, Ginsberg JS. The post-thrombotic syndrome: current knowledge, controversies and directions for future research. Blood Reviews 2002;16(3):155-65.
-
(2002)
Blood Reviews
, vol.16
, Issue.3
, pp. 155-165
-
-
Kahn, S.R.1
Ginsberg, J.S.2
-
21
-
-
19944395865
-
Direct thrombin inhibitors: pharmacology and clinical relevance
-
Kam PC, Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia 2005;60(6):565-74.
-
(2005)
Anaesthesia
, vol.60
, Issue.6
, pp. 565-574
-
-
Kam, P.C.1
Kaur, N.2
Thong, C.L.3
-
22
-
-
84856802635
-
Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
-
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S-94S.
-
(2012)
Chest
, vol.141
, Issue.2
, pp. e419S-e494S
-
-
Kearon, C.1
Akl, E.A.2
Comerota, A.J.3
Prandoni, P.4
Bounameaux, H.5
Goldhaber, S.Z.6
-
23
-
-
78650931192
-
The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT
-
Koster A, Fischer KG, Harder S, Mertzlufft F. The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT. Biologics 2007;1(2):105-12.
-
(2007)
Biologics
, vol.1
, Issue.2
, pp. 105-112
-
-
Koster, A.1
Fischer, K.G.2
Harder, S.3
Mertzlufft, F.4
-
25
-
-
0035836541
-
Clinical investigation and reports. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
-
Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al.for the ARG-911 Study Investigators. Clinical investigation and reports. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103(14):1838-43.
-
(2001)
Circulation
, vol.103
, Issue.14
, pp. 1838-1843
-
-
Lewis, B.E.1
Wallis, D.E.2
Berkowitz, S.D.3
Matthai, W.H.4
Fareed, J.5
Walenga, J.M.6
-
26
-
-
0033673425
-
The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population based study
-
Mohr DN, Silverstein MD, Heit JA, Petterson TM, O'Fallon WM, Melton LJ III. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population based study. Mayo Clinic Proceedings 2000;75(12):1249-56.
-
(2000)
Mayo Clinic Proceedings
, vol.75
, Issue.12
, pp. 1249-1256
-
-
Mohr, D.N.1
Silverstein, M.D.2
Heit, J.A.3
Petterson, T.M.4
O'Fallon, W.M.5
Melton, L.J.6
-
27
-
-
0027529389
-
Venographic assessment of deep vein thrombosis and risk of developing post-thrombotic syndrome: a prospective study
-
Monreal M, Martorell A, Callejas JM, Valls R, Llamazares JF, Lafoz E, et al. Venographic assessment of deep vein thrombosis and risk of developing post-thrombotic syndrome: a prospective study. Journal of Internal Medicine 1993;233(3):233-8.
-
(1993)
Journal of Internal Medicine
, vol.233
, Issue.3
, pp. 233-238
-
-
Monreal, M.1
Martorell, A.2
Callejas, J.M.3
Valls, R.4
Llamazares, J.F.5
Lafoz, E.6
-
28
-
-
85041721216
-
Venous thromboembolic diseases: the management of thromboembolic diseases and the role of thrombophilia testing, 2012
-
(accessed 11 January 2014)
-
National Institute for Health and Care Excellence. Venous thromboembolic diseases: the management of thromboembolic diseases and the role of thrombophilia testing, 2012. guidance.nice.org.uk/CG144 (accessed 11 January 2014).
-
guidance.nice.org.uk/CG144
-
-
-
29
-
-
85041711049
-
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism, 2012
-
(accessed 11 January 2014)
-
National Institute of Health and Care Excellence. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism, 2012. guidance.nice.org.uk/TA261 (accessed 11 January 2014).
-
guidance.nice.org.uk/TA261
-
-
-
30
-
-
80052232522
-
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial
-
Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European Heart Journal 2011;32(22):2781-9.
-
(2011)
European Heart Journal
, vol.32
, Issue.22
, pp. 2781-2789
-
-
Oldgren, J.1
Budaj, A.2
Granger, C.B.3
Khder, Y.4
Roberts, J.5
Siegbahn, A.6
-
32
-
-
0030317948
-
The long-term clinical course of acute deep venous thrombosis
-
Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Annals of Internal Medicine 1996;125(1):1-7.
-
(1996)
Annals of Internal Medicine
, vol.125
, Issue.1
, pp. 1-7
-
-
Prandoni, P.1
Lensing, A.W.A.2
Cogo, A.3
Cuppini, S.4
Villalta, S.5
Carta, M.6
-
33
-
-
79960705415
-
Review Manager (RevMan)
-
5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration
-
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
-
(2012)
-
-
-
34
-
-
85041712895
-
Direct thrombin inhibitors or factor Xa inhibitors for the treatment of pulmonary embolism
-
Robertson L, Kesteven P. Direct thrombin inhibitors or factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database of Systematic Reviews 2014, Issue 1.
-
(2014)
Cochrane Database of Systematic Reviews
, Issue.1
-
-
Robertson, L.1
Kesteven, P.2
-
35
-
-
0033939899
-
The occurrence of the post-thrombotic changes after an acute deep venous thrombosis. A prospective two-year follow-up study
-
Saarinen J, Kallio T, Lehto M, Hiltunen S, Sisto T. The occurrence of the post-thrombotic changes after an acute deep venous thrombosis. A prospective two-year follow-up study. Journal of Cardiovascular Surgery 2000;41(3):441-6.
-
(2000)
Journal of Cardiovascular Surgery
, vol.41
, Issue.3
, pp. 441-446
-
-
Saarinen, J.1
Kallio, T.2
Lehto, M.3
Hiltunen, S.4
Sisto, T.5
-
36
-
-
23044505564
-
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
-
Schulman S, Kearon C, and the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis 2005;3(4):692-4.
-
(2005)
Journal of Thrombosis and Haemostasis
, vol.3
, Issue.4
, pp. 692-694
-
-
Schulman, S.1
Kearon, C.2
-
37
-
-
84862530985
-
A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II)
-
Schulman S, Kakkar AK, Schellong SM, Goldhaber SZ, Henry E, Mismetti P. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood 2011;118:Abstract 205.
-
(2011)
Blood
, vol.118
-
-
Schulman, S.1
Kakkar, A.K.2
Schellong, S.M.3
Goldhaber, S.Z.4
Henry, E.5
Mismetti, P.6
-
38
-
-
85041497311
-
Prevention and management of venous thromboembolism: a national clinical guideline, 2010
-
(accessed 11 January 2014)
-
Scottish Intercollegiate Guidelines Network. Prevention and management of venous thromboembolism: a national clinical guideline, 2010. www.sign.ac.uk/pdf/sign122.pdf (accessed 11 January 2014).
-
-
-
-
39
-
-
84890730197
-
Addressing reporting biases
-
Higgins JPT, Green S (editors), Version 5.1.0 [updated March 2011]. The Cochrane Collaboration
-
Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
-
(2011)
Cochrane Handbook for Systematic Reviews of Interventions.
-
-
Sterne, J.A.C.1
Egger, M.2
Moher, D.3
-
40
-
-
84862585771
-
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabIgatran etexilate in patients after heart valve replacement (RE-ALIGN)
-
Van de Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB, Hartter S, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabIgatran etexilate in patients after heart valve replacement (RE-ALIGN). American Heart Journal 2012;163(6):931-7.
-
(2012)
American Heart Journal
, vol.163
, Issue.6
, pp. 931-937
-
-
Van de Werf, F.1
Brueckmann, M.2
Connolly, S.J.3
Friedman, J.4
Granger, C.B.5
Hartter, S.6
-
41
-
-
0030281338
-
A 14-year study of heparin-induced thrombocytopenia
-
Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. American Journal of Medicine 1996;101(5):502-7.
-
(1996)
American Journal of Medicine
, vol.101
, Issue.5
, pp. 502-507
-
-
Warkentin, T.E.1
Kelton, J.G.2
-
42
-
-
0038344806
-
A novel approach to thrombin inhibition
-
Weitz JI. A novel approach to thrombin inhibition. Thrombosis Research 2003;109(Suppl 1):S17-22.
-
(2003)
Thrombosis Research
, vol.109
, pp. S17-S22
-
-
Weitz, J.I.1
-
43
-
-
0141796729
-
Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis
-
Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. New England Journal of Medicine 2003;349(13):1227-35.
-
(2003)
New England Journal of Medicine
, vol.349
, Issue.13
, pp. 1227-1235
-
-
Wells, P.S.1
Anderson, D.R.2
Rodger, M.3
Forgie, M.4
Kearon, C.5
Dreyer, J.6
|